In contrast, based on an artificial syndrome of inappropriate ADH-secretion (SIADH) model, the SGLT2-inibitor empagliflozin, with its increased urine excretion through osmotic diuresis, has been suggested as a new treatment option for SIADH-induced hyponatremia [30]. Here, AVP is linked to inappropriate ADH syndrome.